Harrow (HROW) Current Assets (2010 - 2026)
Harrow (HROW) posted Current Assets of $229.3 million for Q2 2026, up 1.29% on a QoQ basis from $226.4 million in Q1 2026, and up 48.05% year-over-year from $154.9 million in Q2 2025.
Analysis
Harrow (HROW) Current Assets (2010 - 2026) Analysis & Trends
Harrow has reported Current Assets for 17 years, with the latest figure at $229.3 million in Q2 2026.
- On a quarterly basis, Current Assets rose 48.05% year-over-year to $229.3 million in Q2 2026; TTM through Jun 2026 was $229.3 million, a 48.05% increase from a year earlier, with the FY2025 full-year figure at $211.8 million, up 11.65% from the prior year.
- Current Assets was $229.3 million for Q2 2026 at Harrow, up from $226.4 million in the prior quarter.
- The five-year high for Current Assets was $229.3 million in Q2 2026, with the low at $51.7 million in Q1 2023.
- Average Current Assets over 5 years is $135.7 million, with a median of $139.4 million recorded in 2023.
- The sharpest annual moves came in 2022 and 2024: Current Assets sank 30.78% in 2022, then soared 142.73% in 2024.
- Over 5 years, Current Assets stood at $118.3 million in 2022, then climbed by 17.95% to $139.5 million in 2023, then soared by 35.97% to $189.7 million in 2024, then gained by 11.65% to $211.8 million in 2025, then advanced by 8.29% to $229.3 million in 2026.
- The last three Current Assets figures came in at $229.3 million (Q2 2026), $226.4 million (Q1 2026), and $211.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 41.36 Bn |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn | 36.64 Bn |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - | 4.03 Bn |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 6.03 Bn |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn | 3.48 Bn |
| 10 | Harrow | 1.41 Bn | 1.32 Bn | 50.36 Mn | 229.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 229.31 Mn |
| Mar 31, 2026 | 226.38 Mn |
| Dec 31, 2025 | 211.75 Mn |
| Sep 30, 2025 | 177.60 Mn |
| Jun 30, 2025 | 154.89 Mn |
| Mar 31, 2025 | 169.54 Mn |
| Dec 31, 2024 | 189.65 Mn |
| Sep 30, 2024 | 147.06 Mn |
| Jun 30, 2024 | 139.39 Mn |
| Mar 31, 2024 | 125.46 Mn |
| Dec 31, 2023 | 139.48 Mn |
| Sep 30, 2023 | 110.28 Mn |
| Jun 30, 2023 | 60.30 Mn |
| Mar 31, 2023 | 51.69 Mn |
| Dec 31, 2022 | 118.26 Mn |
| Sep 30, 2022 | 64.07 Mn |
| Jun 30, 2022 | 64.70 Mn |
| Mar 31, 2022 | 62.32 Mn |
| Dec 31, 2021 | 60.66 Mn |
| Sep 30, 2021 | 91.13 Mn |